bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–05–24
two papers selected by
Cliff Dominy



  1. Am J Physiol Heart Circ Physiol. 2026 May 21.
      Ischemic heart disease remains a major global health burden, with ischemia/reperfusion injury representing a critical determinant of myocardial damage. Remote ischemic conditioning (RIC) and differentiated physical exercise regimens have emerged as potential preconditioning strategies enhancing myocardial resilience, and increasing evidence suggests that these cardioprotective effects may, in part, be mediated by targeted delivery of extracellular vesicle (EV)-carried microRNAs (miRNAs). RIC induces rapid alterations in circulating EV cargo, including miRNAs known to promote cell survival, attenuate oxidative stress, and modulate inflammation. This transient yet pronounced miRNA response to RIC indicates a rapid EV-associated molecular change that may be relevant to early signaling events underlying remote organ preconditioning. EV-miRNA content also changes acutely in response to exercise. These changes are associated with vascular remodeling, anti-apoptotic signaling, and metabolic adaptation, suggesting that exercise-induced EVs provide both immediate and sustained cardioprotection, though temporal dynamics remain incompletely defined. Consequently, RIC and exercise elicit distinct yet overlapping EV-miRNA signatures that may affect myocardial preconditioning. Here, we review whether EV-delivered miRNAs elicited by RIC and exercise may contribute to cardioprotection and may be therapeutically exploited in clinical settings such as heart failure and ischemic disease.
    Keywords:  Ischemia-reperfusion; Remote ischemic conditioning; exercise conditioning; extracellular vesicles; miRNA
    DOI:  https://doi.org/10.1152/ajpheart.00954.2025
  2. Front Cardiovasc Med. 2026 ;13 1739634
      Lipoprotein(a) [Lp(a)] is a well-established genetic risk factor for atherosclerotic cardiovascular disease, though its role as a prothrombotic risk factor remains only partially understood. We report the case of a 64-year-old woman with markedly elevated Lp(a) levels (925 nmol/L, reference range < 105 nmol/L) and a history of recurrent major cardiovascular events, despite optimal lipid-lowering and antiplatelet therapies. We confirmed a hypercoagulable profile via comprehensive functional assessment of hemostasis: enhanced thrombin generation, reduced sensitivity to thrombomodulin, platelet hyperreactivity, and increased clot firmness at thromboelastometry - with residual platelet activity despite antiplatelet treatment. This case suggests a possible association between markedly elevated plasma Lp(a) levels and a hypercoagulable profile, which may enhance atherogenesis. Global coagulation and platelet function assays may help identify high-risk patients with elevated Lp(a) levels who may benefit from tailored antithrombotic strategies.
    Keywords:  case report; extracellular vesicles; lipoprotein(a); platelet function assays; prothrombotic risk; thrombin generation; thromboelastometry
    DOI:  https://doi.org/10.3389/fcvm.2026.1739634